FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers
FDA continues to alert healthcare professionals and consumers about the risks of 7-hydroxymitragynine.
FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine
FDA announced seven recent warning letters sent to companies for illegally marketing products containing 7-hydroxymitragynine, also known as 7-OH.
FTC Sends Refunds to Consumers Harmed by Weight-loss Supplement Marketer’s Deceptive Claims and Review Practices
FTC is sending payments totaling more than $409,000 to consumers who purchased weight-loss supplements that were deceptively marketed.
FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain
Patients should only obtain Ozempic with a valid prescription through state-licensed pharmacies, according to FDA.
FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products.
FDA has become aware of reports of adverse events involving compounded topical finasteride products.
Athlete Advisory: What’s New on the 2025 WADA Prohibited List?
Summary of changes to WADA Prohibited List